BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years

UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...
Home/KnloSights/Clinical Trial Updates/BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years